Pharming Group (PHAR)
(Delayed Data from NSDQ)
$10.00 USD
+0.67 (7.18%)
Updated Apr 19, 2024 03:20 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for Pharming Group NV Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 245 | 206 | 199 | 212 | 189 |
Cost Of Goods | 25 | 18 | 21 | 24 | 24 |
Gross Profit | 220 | 188 | 178 | 189 | 165 |
Selling & Adminstrative & Depr. & Amort Expenses | 225 | 170 | 164 | 112 | 97 |
Income After Depreciation & Amortization | -5 | 18 | 14 | 76 | 68 |
Non-Operating Income | -7 | -3 | 10 | -32 | -16 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | 15 | 23 | 44 | 52 |
Income Taxes | -1 | 1 | 7 | 6 | 12 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | 14 | 16 | 38 | 41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -11 | 14 | 16 | 38 | 41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 11 | 31 | 33 | 85 | 74 |
Depreciation & Amortization (Cash Flow) | 16 | 13 | 20 | 8 | 6 |
Income After Depreciation & Amortization | -5 | 18 | 14 | 76 | 68 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 67.46 | 71.97 | 64.23 | 64.03 | NA |
Diluted EPS Before Non-Recurring Items | -0.14 | 0.03 | 0.19 | 0.58 | NA |
Diluted Net EPS (GAAP) | -0.16 | 0.19 | 0.23 | 0.55 | 0.60 |
Fiscal Year end for Pharming Group NV Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 81.20 | 66.70 | 54.90 | 42.54 |
Cost Of Goods | NA | NA | 8.30 | NA | 4.08 |
Gross Profit | NA | NA | 58.40 | NA | 38.47 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 56.50 | 0.00 | 52.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 1.90 | 0.00 | -13.66 |
Non-Operating Income | NA | NA | 1.40 | NA | -3.01 |
Interest Expense | NA | NA | 0.00 | NA | 0.00 |
Pretax Income | NA | NA | 3.30 | NA | -16.67 |
Income Taxes | NA | NA | -0.20 | NA | -4.47 |
Minority Interest | NA | NA | 0.00 | NA | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | NA | 0.00 |
Other Income/Charges | NA | NA | 0.00 | NA | 0.00 |
Income From Cont. Operations | NA | -2.70 | 3.50 | 1.32 | -12.21 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.70 | 3.50 | 1.32 | -12.21 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 67.50 | 69.28 | 65.95 | 64.25 |
Diluted EPS Before Non-Recurring Items | NA | -0.03 | 0.05 | 0.02 | -0.17 |
Diluted Net EPS (GAAP) | NA | -0.04 | 0.05 | 0.02 | -0.17 |